跳至主要内容
临床试验/NCT00211965
NCT00211965已完成3 期

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Adult Patients Receiving an Orthopedic Prosthetic Implant

Nabi Biopharmaceuticals2 个研究点 分布在 1 个国家目标入组 67 人开始时间: 2005年4月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
67
试验地点
2
主要终点
Sero-type specific antibody concentrations

研究概览

简要总结

Staphylococcus aureus (S. aureus) is the most common pathogen encountered in infections associated with orthopedic surgery. StaphVAX® is a bivalent S. aureus types 5 and 8 vaccine which contains the purified capsular polysaccharides that have been implicated as a major factor in the invasiveness of S. aureus. Immunoprophylaxis by vaccinating against S. aureus prior to surgery could provide sufficient antibody concentrations during surgery and the wound healing period so as to decrease the risk of S. aureus infection. This study aims to demonstrate the immunogenicity and safety of a single dose of StaphVAX in patients who are candidates for orthopedic surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 years or older
  • Candidate for knee or hip replacement
  • Expectation of protocol compliance
  • Negative pregnancy test, where appropriate

排除标准

  • Known S. aureus infection in the prior 3 months
  • Infection in the prior 2 weeks
  • Known HIV infection
  • Immunomodulatory drugs
  • Malignancy (other than basal cell or squamous cell carcinoma, carcinoma in situ of the cervix, or early prostate cancer)
  • Hypersensitivity to components of StaphVAX

结局指标

主要结局

Sero-type specific antibody concentrations

时间窗: 6 weeks after study dose

次要结局

  • adverse events(throughout 6 months observation after study dose)
  • Sero-type specific antibody concentrations(various other time points after study dose, up to 26 wk)

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验